We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

The Cardiff Oncology logo.
Product News

Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase II Randomized Trial

Cardiff Oncology, Inc. has announced that the first patient was dosed last month with its investigational drug onvansertib in its Phase II ONSEMBLE trial.
A female scientist stood in a lab.
Product News

Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco

 Thermo Fisher Scientific Inc. and the University of California, San Francisco will accelerate advanced cell therapies for difficult-to-treat conditions from a newly opened cGMP manufacturing facility.
The Predictive Oncology and Cancer Research Horizons logos.
Product News

Predictive Oncology and Cancer Research Horizons Partnered To Develop of Cancer Drugs

Predictive Oncology Inc. together with Cancer Research Horizons, announce that they have partnered to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL™ platform.
The owlstone medical logo.
Product News

Owlstone Medical Enters Partnership To Develop Probes for Early Cancer Detection

Owlstone Medical has announced that it has entered into a Research Agreement with Bicycle Therapeutics plc.
Text within a navy blue badge, "CytoCell IVDR-certified probes"
Product News

OGT First To Achieve IVDR-Certification for FISH Probes

OGT announces that IVDR certification has been granted for eight CytoCell® fluorescence in situ hybridization (FISH) probes important for patient management in hematological cancers and prenatal conditions.
The SonALAsense logo
Product News

SonALAsense Announces Completion of First Cohort in Phase 2 Study of Sonodynamic Therapy for Recurrent Glioblastoma

SonALAsense has announced that the first cohort in Sonodynamic Therapy (SDT)-202 was fully enrolled.
The Personalis logo
Product News

Personalis Selected for Clinical Research After Successful Evaluation of Residual Disease Assay

Personalis, Inc. has announced it will continue its collaboration with AstraZeneca to explore ultra-sensitive molecular residual disease measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development.
Three circular images of the AML mouse model.
Product News

TransCure bioServices Delivers CDX Mouse Models To Advance AML Preclinical Studies

TransCure bioServices has developed cell line-derived xenograft mouse models that will change how researchers tackle the preclinical studies of cancer therapies to treat acute myeloid leukemia.
Syringe and three vials of vaccine.
Product News

Voltron Therapeutics, Inc. Announces Sponsored Research Agreement With the Massachusetts General Hospital, Harvard Medical School, To Initiate a Pre-Clinical Immuno-Oncology Trial

Voltron Therapeutics, Inc. has signed a new Sponsored Research Agreement with the Vaccine and Immunotherapy Center at Massachusetts General Hospital, Harvard Medical School to initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen in prostate, renal cell and urothelial cancers, adding important potential indications to its growing pipeline.
The Akamis Bio logo
Product News

Akamis Bio, Parker Institute for Cancer Immunotherapy and Cancer Research Institute Expand Partnership

Akamis Bio has announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy to include a clinical collaboration with the Cancer Research Institute that will focus on advancing novel treatments for pancreatic cancer.